Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber
Jeffrey H
JH
Center for Outcomes Research, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. silber@email.CHOP.edu
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000009:adverse effects*; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011379:Prognosis; D011929:Razoxane / Q000627:therapeutic use*; D020107:Troponin T / Q000097:blood*
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D002614:Chelating Agents; D020107:Troponin T; D011929:Razoxane; D004317:Doxorubicin